Back to Search
Start Over
Efmoroctocog Alfa: A Review in Haemophilia A.
- Source :
-
Drugs [Drugs] 2021 Nov; Vol. 81 (17), pp. 2035-2046. Date of Electronic Publication: 2021 Nov 07. - Publication Year :
- 2021
-
Abstract
- Efmoroctocog alfa (Elocta <superscript>®</superscript> , Eloctate <superscript>®</superscript> , Eloctateâ„¢), an extended half-life (EHL) recombinant factor VIII (rFVIII)-Fc fusion protein, is approved for the treatment and prophylaxis of bleeding in patients with haemophilia A. The efficacy of efmoroctocog alfa in the prevention and treatment of bleeding in previously treated patients (PTPs) and previously untreated patients (PUPs) with severe haemophilia A has been demonstrated in phase III studies; this includes its use in the perioperative setting (in PTPs). Furthermore, the effectiveness of efmoroctocog alfa in clinical practice has been confirmed in numerous real-world studies; compared with conventional, standard half-life (SHL) FVIII products, prophylaxis with this EHL FVIII product achieved similar or reduced bleeding rates with fewer injections. Efmoroctocog alfa was generally well tolerated; inhibitors occurred in approximately one-third of PUPs in a phase III study. Efmoroctocog alfa is an established and effective EHL FVIII replacement therapy for the management of haemophilia A. Compared with SHL FVIII products, EHL FVIII products such as efmoroctocog alfa have the potential to optimise prophylactic outcomes by decreasing the burden of treatment or increasing the level of bleed protection.<br /> (© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
- Subjects :
- Area Under Curve
Clinical Trials, Phase III as Topic
Factor VIII adverse effects
Factor VIII pharmacokinetics
Half-Life
Hemorrhage prevention & control
Humans
Immunoglobulin Fc Fragments adverse effects
Male
Metabolic Clearance Rate
Recombinant Fusion Proteins adverse effects
Recombinant Fusion Proteins pharmacokinetics
Factor VIII therapeutic use
Hemophilia A drug therapy
Immunoglobulin Fc Fragments therapeutic use
Recombinant Fusion Proteins therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1950
- Volume :
- 81
- Issue :
- 17
- Database :
- MEDLINE
- Journal :
- Drugs
- Publication Type :
- Academic Journal
- Accession number :
- 34743314
- Full Text :
- https://doi.org/10.1007/s40265-021-01615-w